Tweet
Is it possible to compare exome data generated on an Ion Proton with exome data generated on an Illumina platform? I have sequenced germline samples on the proton and have sequenced tumour samples using Illumina and I am wondering if it will be at all possible to compare?
-
-
It's certainly possible to generate useful data in this case, but there will be a lot more noise than if everything was the same platform. The biggest issue will probably be not the difference in platforms, but the difference in baits/kits; if the tumor sample has 0 coverage for some gene that has 50x coverage in the control, you won't really know if that's because the gene got deleted, or because the capture was ineffective in that area.
I suggest you calculate the cost of person-hours spent analyzing this data versus the cost of rerunning on or the other so that all data is from the same platform. It does not make sense to spend $50k chasing down and validating spurious differences that could be wiped out en masse with $1k of sequencing. The alternate platform's data is not wasted in this case, either, as it can increase confidence in variations found (or not found) in the other platform. -
Yes, that is what I am wondering - would it be much better to sequence both on the same platform?Comment
-
Hi rjones89. You could compare the data from 2 platforms, but for the INDELS. The SNP variants called could be compared. Let me know if you need help with this, if you are interested in analysis of only the SNP variants.
We (Genotypic Technology - www.genotypic.co.in) are a Genomics services provider based in India. Write to me at [email protected] with your query and we can discuss more on this. I will work out the best possible price for analysis work.
Thanks.Comment
-
Ion Torrent just released the HiQ chemistry for the Ion Torrent. They claim that the indel problem has been resolved.Comment
-
-
Hey there...we keep commercial activities in the Vendor Forum and discourage overt commercial posting...please contact me if you want permission to post in the Vendor Forum. Thanks.
Originally posted by kushald View PostComment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment